Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

Author(s):
Wick, W.; Gorlia, T.; Bady, P.; Platten, M.; Bent, M.J. van den; Taphoorn, M.J.B.; Steuve, J.; Brandes, A.A.; Hamou, M.F.; Wick, A.; Kosch, M.; Weller, M.; Stupp, R.; Roth, P.; Golfinopoulos, V.; Frenel, J.S.; Campone, M.; Ricard, D.; Marosi, C.; Villa, S.; Weyerbrock, A.; Hopkins, K.; Homicsko, K.; Lhermitte, B.; Pesce, G.; Hegi, M.E.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-10-01
Language
English
Is part of
Clinical Cancer Research (2016), Vol. 22, no. 19, p. 4797-4806
hdl
1887/113092
doi
10.1158/1078-0432.CCR-15-3153